Alector Stock Today
| ALEC Stock | USD 1.96 0.14 7.69% |
PerformanceGood
| Odds Of DistressSmall
|
Alector is trading at 1.96 as of the 8th of February 2026, a 7.69 percent increase since the beginning of the trading day. The stock's open price was 1.82. Alector has about a 31 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 10th of November 2025 and ending today, the 8th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of February 2019 | Category Healthcare | Classification Health Care |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. The company was founded in 2013 and is headquartered in South San Francisco, California. Alector operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 109.15 M outstanding shares of which 6.49 M shares are presently shorted by private and institutional investors with about 5.55 trading days to cover. More on Alector
Moving together with Alector Stock
Moving against Alector Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Alector Stock Highlights
| CEO | Arnon Rosenthal | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBy employing borrowed capital, Alector can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on Alector's use of financial leverage and reveals what portion of Alector's asset base relies on creditor financing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alector (ALEC) is traded on NASDAQ Exchange in USA and employs 156 people. Alector is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 213.94 M. Alector conducts business under Biotechnology sector and is part of Health Care industry. The entity has 109.15 M outstanding shares of which 6.49 M shares are presently shorted by private and institutional investors with about 5.55 trading days to cover.
Alector currently holds about 808.85 M in cash with (229.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Alector Probability Of Bankruptcy
Ownership AllocationAlector holds a total of 109.15 Million outstanding shares. The majority of Alector outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alector to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alector. Please pay attention to any change in the institutional holdings of Alector as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Alector Ownership Details
Alector Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Renaissance Technologies Corp | 2025-06-30 | 1.3 M | |
| Deerfield Management Co | 2025-06-30 | 1.1 M | |
| 5am Venture Management, Llc | 2025-06-30 | 995.8 K | |
| Deutsche Bank Ag | 2025-06-30 | 989.7 K | |
| Vestal Point Capital Lp | 2025-06-30 | 977 K | |
| Dafna Capital Management Llc | 2025-06-30 | 912.9 K | |
| Ikarian Capital, Llc | 2025-06-30 | 900 K | |
| Sio Capital Management, Llc | 2025-06-30 | 845.5 K | |
| Northern Trust Corp | 2025-06-30 | 658.2 K | |
| Fmr Inc | 2025-06-30 | 15 M | |
| Blackrock Inc | 2025-06-30 | 8 M |
Alector Historical Income Statement
Alector Stock Against Markets
Alector Corporate Management
| Virginia MBA | Chief Strategy | Profile | |
| Norah Conway | Program Portfolio | Profile | |
| Gary MD | Chief Officer | Profile | |
| Katie Hogan | Senior Relations | Profile |
Already Invested in Alector?
The danger of trading Alector is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alector is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alector. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alector is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alector offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alector's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alector Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alector Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alector. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. For information on how to trade Alector Stock refer to our How to Trade Alector Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Will Biotechnology sector continue expanding? Could Alector diversify its offerings? Factors like these will boost the valuation of Alector. If investors know Alector will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alector data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.86) | Earnings Share (1.06) | Revenue Per Share | Quarterly Revenue Growth (0.79) | Return On Assets |
Investors evaluate Alector using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Alector's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Alector's market price to deviate significantly from intrinsic value.
Understanding that Alector's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alector represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Alector's market price signifies the transaction level at which participants voluntarily complete trades.